Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Bruce E SandsGeert R A M D'HaensDavid B ClemowPeter M IrvingJordan T JohnsTheresa Hunter GibbleMaria T AbreuScott LeeTadakazu HisamatsuTaku KobayashiMarla C DubinskySeverine VermeireCorey A SiegelLaurent Peyrin-BirouletRichard E MosesJoe MilataVipin AroraRemo PanaccioneAxel DignassPublished in: Inflammatory bowel diseases (2024)
Endoscopic, histologic, symptomatic, and quality-of-life outcomes support the long-term benefit of mirikizumab treatment up to 104 weeks in patients with ulcerative colitis, including biologic-failed patients, with no new safety concerns.